Development[investors.teleflex.com] 610-948-2836[Back to Newsroom] Teleflex Announces Fourth Quarter 2025 Earnings Conference Call InformationFeb 17, 2026 6:30 AM Eastern Standard Time# Teleflex Announces Fourth Quarter 2025 Earnings Conference Call InformationShare--- WAYNE, Pa.--([BUSINESS WIRE])--Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its fourth quarter 2025 financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, February 26, 2026.To par ...

Core Viewpoint - TFX is undergoing a significant strategic adjustment announced in December 2025, which is expected to continue into 2026 [1] Group 1: Company Project Progress - TFX announced the sale of its emergency care, interventional urology, and OEM businesses for $2.03 billion, with board approval and expected completion in the second half of 2026, subject to regulatory approvals [2] - The company anticipates a post-tax net gain of approximately $1.8 billion from the transaction, which will be used to optimize its capital structure [2] Group 2: Fund Movements - In conjunction with the business sale, TFX's board approved a stock repurchase plan of up to $1 billion, primarily funded by the proceeds from the sale, aimed at enhancing shareholder returns [3] Group 3: Strategic Advancement - Following the divestiture of non-core businesses, TFX will focus more on high-growth areas such as vascular access, interventional, and surgical sectors [4] - The integration effects of the previously announced acquisition of the BodiLink vascular intervention business (approximately €760 million) will also be closely monitored, as it may impact mid- to long-term performance [4]

Company Overview - Teleflex is a diversified medical device company specializing in devices for critical care and surgical procedures, with a global presence and a broad portfolio of proprietary products [6] - The company generates revenue primarily through the design, manufacturing, and global distribution of proprietary medical devices used in hospitals and healthcare settings [8] - Key product lines include Arrow catheters, UroLift System, and vascular closure devices, addressing the needs of hospitals and healthcare providers [8] Financial Performance - As of February 4, Teleflex shares were priced at $106.00, down 38.7% over the past year, underperforming the S&P 500's roughly 14% gain in the same period [3] - Teleflex posted GAAP revenue of $913 million in the most recent quarter, reflecting a year-over-year increase of 19.4%, with adjusted diluted EPS rising to $3.67 [10] - The company has narrowed its full-year revenue guidance and lifted adjusted EPS expectations to a range of $14.00 to $14.20 [10] Investment Position - Tejara Capital Ltd increased its stake in Teleflex by 69,700 shares, with an estimated transaction value of approximately $8.45 million [2] - This acquisition raised Teleflex's stake to 2.23% of Tejara's 13F assets under management as of December 31 [3] - The total position value in Teleflex rose by $8.50 million quarter over quarter, including share additions and price fluctuations [2] Market Context - Teleflex is undergoing a transition that has impacted its stock price, which is down nearly 39% over the past year despite ongoing operating growth [9] - The company's focus on single-use medical devices and recurring hospital demand provides a different risk profile compared to Tejara's other higher-beta positions in energy, shipping, and biotech [11]

Upgrades - CoStar Group (CSGP) upgraded to Buy from Neutral with an $80 price target due to low expectations, past peak investment, and momentum from Homes.com, along with an anticipated AI-driven product update [2] - Teleflex (TFX) upgraded to Buy from Hold with a $138 price target as the company plans to sell its acute care, interventional urology, and manufacturing businesses for $2 billion, expecting significant earnings accretion from share repurchases and debt repayment by 2027 [3] - CoreWeave (CRWV) upgraded to Buy from Hold with a $140 price target, with a solid medium-term outlook ahead of the Q4 report [3] - Affirm (AFRM) upgraded to Buy from Hold with a $100 price target after submitting an application to establish Affirm Bank, which could be a game-changer [4] - Target (TGT) upgraded to Peer Perform from Underperform without a price target, with a wide margin of safety despite reduced estimates due to the company's owned real estate [4] Downgrades - Procter & Gamble (PG) downgraded to Hold from Buy with a price target of $156, up from $150, as the pace of recovery is expected to drag [5] - Stryker (SYK) downgraded to Hold from Buy with a $387 price target following a transfer in analyst coverage, with a well-understood valuation reflecting a "beat/raise precedent" [5] - Insulet (PODD) downgraded to Hold from Buy with a $294 price target after a transfer in analyst coverage, noting that competitive advantages may narrow [5] - Matador (MTDR) downgraded to Equal Weight from Overweight with a price target of $47, down from $61, due to stock valuation incorporating structural considerations and recent productivity variability [5] - SkyWater Technology (SKYT) downgraded to Hold from Buy with a price target of $35, up from $24, after agreeing to be acquired by IonQ for $35 per share or $1.88 billion [5]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Teleflex Incorporated and its executives following the abrupt departure of CEO Liam Kelly, which led to a significant drop in the company's stock price [1][3]. Group 1: Company Developments - On January 8, 2026, Teleflex announced the immediate departure of Liam Kelly as Chairman, President, and CEO [3]. - Following this announcement, Teleflex's stock price decreased by $16.52 per share, representing a 13.06% decline, closing at $110.01 per share [3]. Group 2: Legal Investigation - Pomerantz LLP is representing investors in investigating claims against Teleflex regarding possible securities fraud or other unlawful business practices [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action [2].

Core Insights - Teleflex has parted ways with CEO Liam Kelly, appointing Stuart Randle as interim president and CEO while searching for a permanent replacement [3][8] - The leadership change is part of a transformation strategy following the announcement of divesting three business units for approximately $2 billion [5][8] - Teleflex has revised its revenue guidance for 2025 to $3.27 billion to $3.28 billion, down from a previous estimate of $3.31 billion to $3.32 billion, citing softer demand for certain medical devices [7][8] Leadership Changes - Liam Kelly, who became CEO in 2018, has left the company without a permanent successor [3] - Stuart Randle, a board member since 2009 and former CEO of Ivenix, has been appointed as interim president and CEO [4][5] - Stephen Klasko has taken over as chairman of the board following Kelly's departure [3] Business Strategy - Teleflex is in the process of closing the $1.5 billion sale of its OEM business and the $530 million sale of its acute care and interventional urology units [5][6] - The divestitures will allow Teleflex to focus on its vascular access, interventional, and surgical businesses [6] Financial Outlook - The company expects a revenue reduction of just over 1% at the midpoint due to lower-than-expected demand for intra-aortic balloon pumps and catheters in the U.S. and Asia [7] - The revised revenue guidance reflects challenges in the OEM business and delays in purchase orders [7]

Core Viewpoint - Teleflex Incorporated (TFX) experienced a significant decline in share price following leadership changes and a lowered revenue outlook for the year [1]. Group 1: Leadership Changes - Stuart Randle has been appointed as Interim President and Chief Executive Officer, effective immediately, succeeding Liam Kelly, who has stepped down from his roles as Chairman, President, and CEO [1]. Group 2: Stock Performance - Shares of Teleflex fell by 11.32 percent, dropping $14.32 to $112.21 from a previous close of $126.53 [1][2]. - The stock opened at $112.50 and traded within a range of $108.39 to $115.00 during the session on the New York Stock Exchange [2]. - Trading volume reached approximately 1.38 million shares, significantly higher than the average volume of about 0.64 million shares [3]. Group 3: Historical Context - Teleflex's shares have fluctuated within a 52-week range of $102.58 to $185.94 [3].

Leadership Changes - Teleflex Incorporated has appointed Stuart Randle as Interim President and CEO, succeeding Liam Kelly, who has stepped down from his roles [1] - Stephen Klasko has been appointed as Chairman of the Board [1][2] Revenue Outlook - The company has lowered its full-year revenue outlook for 2025 to a range of $3.270 billion to $3.278 billion, down from the previous guidance of $3.305 billion to $3.320 billion [3] - The revision is attributed to softer-than-expected demand for intra-aortic balloon pumps and catheters in the U.S. and Asia, delays in certain OEM purchase orders, and lower overall order volumes across parts of its portfolio [3] Strategic Focus - Teleflex is transitioning to a more focused, higher-growth organization following the announced sale of its Acute Care, Interventional Urology, and OEM businesses [3] - The Board believes this leadership transition is timely to best position the company for future growth [3]

Financial Information - Teleflex Incorporated announced estimated preliminary financial information for the full year ended December 31, 2025, on January 8, 2026[4]. Leadership Changes - Liam J. Kelly departed as President and CEO effective January 7, 2026, with Stuart A. Randle appointed as Interim President and CEO starting January 8, 2026[5][6]. - The company is engaging Spencer Stuart to assist in the search for a permanent President and CEO[5]. Compensation and Benefits - Mr. Randle's compensation includes a monthly stipend of $140,000 and a restricted stock grant valued at $1.5 million, to be granted on January 13, 2026[10]. - Mr. Kelly's severance benefits are contingent upon his execution of a release of claims, with outstanding equity awards receiving age and service vesting treatment[11]. Transition Details - The transition matters were detailed in a press release dated January 8, 2026, which is attached as Exhibit 99.1[12].

Leadership Changes - Stuart Randle has been appointed as Interim President and CEO of Teleflex, succeeding Liam Kelly, who has departed from the company [1] - Dr. Stephen Klasko has been appointed as Chairman of the Board [1][2] - The Board has engaged Spencer Stuart to assist in the search for a permanent CEO [2] Business Strategy and Focus - Teleflex is transitioning to a more focused, higher-growth organization following the announced sale of its Acute Care, Interventional Urology, and OEM businesses [3] - The leadership transition is aimed at positioning the company for future growth in core critical care and high-acuity hospital markets [3] Financial Performance Update - The company expects full year 2025 revenue to be between $3.270 billion and $3.278 billion, a decrease from previous guidance of $3.305 billion to $3.320 billion [4] - The revenue reduction is primarily due to lower than expected demand for intra-aortic balloon pumps and catheters in the U.S. and Asia, as well as delays in OEM purchase orders [5] Future Reporting - Teleflex plans to report its full fourth quarter and full year 2025 financial results in late February or early March 2026 [7]